Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomesNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today
ProActive study shows Natera's Prospera Kidney™ test detects rejection five months before biopsyNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from